Stockholm, Sweden

Laura Goobar-Larsson


Average Co-Inventor Count = 4.6

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2002-2006

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations of Laura Goobar-Larsson

Introduction

Laura Goobar-Larsson is a prominent inventor based in Stockholm, Sweden. She has made significant contributions to the field of antiviral research, particularly in the development of compounds that inhibit viral infections. With a total of four patents to her name, her work has the potential to impact the treatment of serious viral diseases.

Latest Patents

Among her latest patents is an antiviral composition comprising glycine amide. This invention relates to the discovery that certain tripeptide amides and glycine amide can be utilized to inhibit viral infections, including human immunodeficiency virus (HIV) infection. The patent outlines medicaments that include these compounds and methods for their use in preventing and treating viral infections. Another notable patent focuses on tripeptide amides that block viral infectivity. This invention also targets HIV and provides methods for using these compounds in the prevention and treatment of viral infections.

Career Highlights

Laura Goobar-Larsson is associated with Tripep AB, a company dedicated to advancing antiviral therapies. Her work at Tripep AB has positioned her as a key figure in the fight against viral diseases. Her innovative approaches and discoveries have garnered attention in the scientific community.

Collaborations

Laura has collaborated with notable researchers, including Anders Vahlne and David Van Der Spoel. These collaborations have further enriched her research and contributed to the development of her patents.

Conclusion

Laura Goobar-Larsson's contributions to antiviral research through her patents demonstrate her commitment to advancing medical science. Her innovative work has the potential to make a significant impact on the treatment of viral infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…